Clopidogrel intravenous - Ligand Pharmaceuticals

Drug Profile

Clopidogrel intravenous - Ligand Pharmaceuticals

Alternative Names: Captisol-Enabled® clopidogrel; Clopidogrel intravenous - CyDex; MDCO-157; PM 103; sulfobutylether β-cyclodextrin-enabled clopidogrel

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CyDex Pharmaceuticals; Prism Pharmaceuticals
  • Developer Ligand Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary thrombosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2013 The Medicines Company and Ligand Pharmaceuticals terminate their licensing agreement for intravenous clopidogrel
  • 31 Jan 2013 The Medicines Company completes a phase I trial in healthy volunteers in France (NCT01860105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top